Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group Guidelines

  

Authors:	Mosele, M. F.; Westphalen, C. B.; Stenzinger, A.; Barlesi, F.; Bayle, A.; Bièche, I.; Bonastre, J.; Castro, E.; Dienstmann, R.; Krämer, A.; Czarnecka, A. M.; Meric-Bernstam, F.; Michiels, S.; Miller, R.; Normanno, N.; Reis-Filho, J.; Remon, J.; Robson, M.; Rouleau, E.; Scarpa, A.; Serrano, C.; Mateo, J.; André, F.
Title:	Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group
Abstract:	Background: Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice. Methods: The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility. Results: As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer. Moreover, it is recommended to carry out tumour NGS in clinical research centres and under specific circumstances discussed with patients. In this updated report, the consensus within the group has led to an expansion of the recommendations to encompass patients with advanced breast cancer and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary. Finally, ESMO recommends carrying out tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available. Conclusion: Tumour NGS is increasingly expanding its scope and application within oncology with the aim of enhancing the efficacy of precision medicine for patients with cancer. © 2024 The Author(s)
Keywords:	advanced cancer; liver cell carcinoma; cancer patient; genetic analysis; clinical practice; colorectal cancer; homologous recombination; gastrointestinal stromal tumor; metastasis; ovary cancer; oncology; tumor marker; monoclonal antibody; prostate cancer; cost effectiveness analysis; health economics; fusion gene; soft tissue sarcoma; clinical research; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; clinical decision making; bile duct carcinoma; thyroid cancer; cancer of unknown primary site; mammalian target of rapamycin inhibitor; health care access; epidermal growth factor receptor kinase inhibitor; personalized medicine; non small cell lung cancer; protein kinase b inhibitor; b raf kinase inhibitor; pancreatic ductal carcinoma; selective estrogen receptor modulator; mitogen activated protein kinase kinase inhibitor; clonal hematopoiesis; immune checkpoint inhibitor; high throughput sequencing; bispecific antibody; advanced breast cancer; human; article; precision medicine; next-generation sequencing (ngs); oncogenomics; antibody drug conjugate; escat
Journal Title:	Annals of Oncology
Volume:	35
Issue:	7
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2024-07-01
Start Page:	588
End Page:	606
Language:	English
DOI:	10.1016/j.annonc.2024.04.005
PUBMED:	38834388
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195046104&doi=10.1016%2fj.annonc.2024.04.005&partnerID=40&md5=21f85058406b864eb3c098bc18aacfea
Notes:	Erratum published at DOI: 10.1016/j.annonc.2024.11.010 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/216812